Premium
Helius Medical Technologies Inc (HSDT)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's first product, known as the Portable Ne... Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's first product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. The company derives its revenue from Product Sales, fees and; license sources. Show more
--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis...
NEWTOWN, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
--128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by end of January-- --The stroke registrational...
NEWTOWN, Pa., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic...
-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1644 | -22.3369565217 | 0.736 | 0.7799 | 0.5436 | 338978 | 0.64182792 | CS |
| 4 | -0.0972 | -14.533492823 | 0.6688 | 1.6 | 0.5436 | 8677242 | 0.97060723 | CS |
| 12 | -0.0464 | -7.50809061489 | 0.618 | 1.6 | 0.4151 | 5127983 | 0.93447443 | CS |
| 26 | -0.1384 | -19.4929577465 | 0.71 | 1.6 | 0.373 | 2460951 | 0.91080776 | CS |
| 52 | -6.2484 | -91.6187683284 | 6.82 | 9.5 | 0.373 | 1440833 | 1.37295762 | CS |
| 156 | -207.4284 | -99.7251923077 | 208 | 238 | 0.373 | 1132026 | 21.77404444 | CS |
| 260 | -1749.4284 | -99.9673371429 | 1750 | 1890 | 0.373 | 790685 | 145.20086954 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
